Tumor immune evasion through loss of MHC class-I antigen presentation.

Abstract

CD8 T cells recognize cancers when they detect antigenic peptides presented on a tumor's surface MHC-I molecules. Since MHC-I antigen presentation is not essential for cell growth or survival, many cancers inactivate this pathway, and thereby escape control by CD8 T cells. Such immune evasion allows cancers to progress and also become resistant to CD8 T- cell-based immunotherapies, such as checkpoint blockade. Here, we review recent findings about the various different mechanisms that cancers use to impair antigen presentation, the consequence of such changes, and, in some cases, the potential to reverse these defects.

• Authors: Gulce Sari, Kenneth L Rock
• Journal: Current opinion in immunology (Curr Opin Immunol) Vol. 83 Pg. 102329 (08 2023) ISSN: 1879-0372 [Electronic] England
• PMID: 37130455 (Publication Type: Journal Article, Review, Research Support, N.I.H., Extramural)
• Copyright: Published by Elsevier Ltd.

Chemical References

• Histocompatibility Antigens Class I

Topics

• Humans
• Antigen Presentation
• Tumor Escape
• Histocompatibility Antigens Class I
• CD8-Positive T-Lymphocytes
• Neoplasms
• Immune Evasion